Clinical Trials Logo

Clinical Trial Summary

The primary objective is to determine the efficacy of ST266 eye drops in healing persistent epithelial defects (PED). After 8 weeks of randomized, double-blind treatment, non-healers will enter into an additional 8-week open-label ST266 treatment period. All patients will be followed for 3-months post-treatment for monitoring of safety and maintenance of re-epithelialization.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

  • Persistent Corneal Epithelial Defect

NCT number NCT05066698
Study type Interventional
Source Noveome Biotherapeutics, formerly Stemnion
Contact Anne Urling
Phone 412-402-9976
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date October 13, 2021
Completion date February 2023

See also
  Status Clinical Trial Phase
Completed NCT00988494 - Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect Phase 2
Completed NCT03687632 - ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects Phase 2
Completed NCT02979912 - Autologous Platelet Lysate in Corneal Epithelial Defects Phase 1/Phase 2